<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04212637</url>
  </required_header>
  <id_info>
    <org_study_id>38RC18.214</org_study_id>
    <nct_id>NCT04212637</nct_id>
  </id_info>
  <brief_title>Study of Eye Movements (EYE) as Early Markers of Brain Dysfunction (BRAIN) in Parkinson's Disease (PARK)</brief_title>
  <acronym>eyebrainpark</acronym>
  <official_title>Study of Eye Movements (EYE) as Early Markers of Brain Dysfunction (BRAIN) in Parkinson's Disease (PARK)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratoire de Psychologie et NeuroCognition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identify the neural bases of eye movements during visual tasks and their dysfunction at early
      stages of Parkinson disease (de novo).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRI images</measure>
    <time_frame>1 hour</time_frame>
    <description>Functional and anatomical brain volumes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eye latency</measure>
    <time_frame>1 hour</time_frame>
    <description>latency (milliseconds) of ocular saccades</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eye amplitude</measure>
    <time_frame>1 hour</time_frame>
    <description>amplitude (degree) of ocular saccades</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRI exam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parkinson patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRI exam</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Examine BOLD activity in relation to eye movements measures</description>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Parkinson patient</arm_group_label>
    <other_name>eyetracking</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for all:

          -  Visual acuity normal or corrected to normal

          -  Affiliation to a social security scheme (copy of the vital card in support)

          -  Signed informed consent

          -  Medical examination according to the participation in the MRI examination

          -  MMSE score&gt; 23/30

        For Parkinson patient:

          -  Diagnosis of Parkinson's disease

          -  Presence of asymmetric bradykinesia and rest tremor and / or stiffness

          -  Hoehn &amp; Yahr Stadium I-II / V

        Exclusion Criteria for all:

          -  Unprotected Majors unable to express their consent

          -  Protected Major (Persons mentioned in Articles L1121-5,6 and 8 of the public health
             code)

          -  Significant hearing or motor impairment

          -  Past or present neuropsychiatric pathology (except benign epilepsy)

          -  Taking narcotics and / or drugs for neurocognitive purposes

          -  Existence of a severe condition in general (cardiac, respiratory, hematological,
             renal, hepatic, cancerous)

          -  Any other neurodegenerative pathology or treatment that may affect the oculomotor
             control

        For Parkinson patient:

          -  Treatment for Parkinson's disease (except the inhibitors of monoaminoxidase B or
             MAO-B, such as selegiline and rasagiline).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carole PEYRIN, PhD</last_name>
    <phone>(0)4 7682-5879</phone>
    <phone_ext>0033</phone_ext>
    <email>carole.peyrin@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Louise KAUFFMANN</last_name>
    <email>louise.kauffmann@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Grenoble-Alpes</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Tiphaine Montagnon</last_name>
      <phone>476766814</phone>
      <phone_ext>0033</phone_ext>
      <email>tmontagnon@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Arnaud ATTYE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>December 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2019</study_first_posted>
  <last_update_submitted>December 26, 2019</last_update_submitted>
  <last_update_submitted_qc>December 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

